Skip to search formSkip to main contentSkip to account menu

AB 1010

Known as: AB-1010, AB1010 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

masitinibmasitinib mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A
Among challenges of targeted therapies is the activation of alternative pro-survival signaling pathways in cancer cells… 
2019
2019
AB1010 MACROPHAGE ACTIVATION SYNDROME: A CASE SERIES OF 16 PATIENTS
Background Macrophage activation syndrome (MAS) is a severe complication of several rheumatologic diseases, being of special… 
2018
2018
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
Purpose Receptor tyrosine kinase inhibitors (RTKIs) are used as targeted therapies for patients diagnosed with cancer with highly… 
Review
2018
Review
2018
AB1010 Risk of infection in patients with rheumatoid arthritis taking denosumab concurrent with biologic therapy
Background Apart from Denosumab effects on bone, there are some promising data on its inhibitory effect on structural damagesin… 
2018
2018
Evaluation of novel optical imaging and therapeutic agents for the detection and treatment of bladder cancer.
................................................................................................... 50 INTRODUCTION… 
2016
2016
Abstract 4868: Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma
Melanoma causes the greatest morbidity and mortality of all skin cancers and often harbors amplifications or activating mutations… 
2016
2016
Abstract 4739: The upregulation of cyclooxygenase-2 protein expression by receptor tyrosine kinase inhibitors in bladder cancerin vitro
Several types of cancer, including transitional cell carcinoma (TCC) overexpress several receptor tyrosine kinases (RTKs… 
2013
2013
AB1010 The absence of the diagnosis of osteoporosis, in patients with hip fractures due to fragility
Background Osteoporosis is a disease whose risk factors are well known, in spite of which remainsunderdiagnosed until a fracture… 
Highly Cited
2009
Highly Cited
2009
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
IntroductionSince current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate… 
2007
2007
FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.
The t(4;14)(p16;q32), found in 15% of multiple myeloma (MM) cases, is associated with a short time to progression (TTP) despite a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)